HOME >> BIOLOGY >> NEWS
Gene therapy for muscular dystrophy

In a study of Muscular Dystrophy, scientists at the University of Pennsylvania School of Medicine have found that a common delivery system used in treating the disease through gene therapy may trigger an immune response in mice unless it is used in combination with a muscle-specific promoter that localizes the expression of genetic material.

The study findings are published in the new issue of the journal Human Gene Therapy.

Even when you use low-levels of a promoter that is not restricted to the afflicted area, you run the risk that you will immunize the patient against the very protein you are trying to get made, said H. Lee Sweeney, PhD, chairman of the Department of Physiology at Penn and lead author of the study. This is relevant because some of the clinical trials that have been started are not using restricted promoters. The journal wanted to get this message out there.

In their published findings, the Penn researchers state that it is crucial to establish which method should be used before expanding clinical trials.

The scientists used two groups of mice that had been engineered to lack a protein called gamma sarcloc-glycan (gsg) in their muscles, which is the same protein that is missing in muscluar dystrophy (MD).

The researchers administered the protein to both groups of mice by enclosing the gsg in the recombinant adeno-associated virus (rAAV) a commonly used vector that has been described in previous scientific research as non-immunogenic.

In one group of mice, the rAAV included a cytomegalovirus (CMV) promoter -- which will express the DNA material it carries in any tissue. The results Sweeney found: Although we didnt see the immune response in the CMV promoter in a large percentage of the mice we did see it.

In the second group of mice, when the rAAV that contained the gsg material was delivered under the control of the muscle creatine kinase promoter which is muscle-specific -- there was no immune response.

What
'"/>

Contact: Ellen O'Brien
ellen.obrien@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
21-Jan-2001


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
Cached News: